Bosentan in Treatment of Pulmonary Arterial Hypertension
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00266162 |
Recruitment Status :
Completed
First Posted : December 16, 2005
Last Update Posted : May 7, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Eisenmenger Syndrome | Drug: Bosentan administration | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Enrollment : | 60 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Therapy of Pulmonary Arterial Hypertension (PAH) With Bosentan in Patients With Eisenmenger Syndrome |
Study Start Date : | August 2004 |
Actual Primary Completion Date : | February 2008 |
Actual Study Completion Date : | February 2008 |

- maximal exercise tolerance (walking distance in the 6-minute walking test)
- peripheral oxygen saturation (SatO2)
- pulmonary-systemic ratio of arterial resistance (Rp:Rs)
- NYHA class
- increase in pulmonary reagibility by bosentan therapy
- normalisation of vasoactive mediators by bosentan therapy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Non-specific:
- Written informed consent obtained
-
Specific:
- Age at least 18 years
- Presence of cyanosis with < 93 % arterial oxygen saturation (measured by transcutaneous pulse oximetry)
- Clinical indication for the invasive diagnostic procedures planned for the study is given; this is evaluated on the basis of observation before, during and after medicinal treatment)
- Presence of PAH as diagnosed by invasive methods with Rp:Rs > 0.75 measured at rest, before testing of pulmonary vasodilatory reserve
-
One of the following diagnoses:
- non-corrected large congenital shunting defect at atrial, ventricular or arterial level: PAPVD, ASD, SVD, VSD, AVSD, TAC, APW, PDA, or a combination of these.
- Surgically corrected shunting defect (diagnoses as above) with significant residual defect
- Other diagnoses with univentricular physiology/haemodynamics.
Exclusion Criteria:
-
Non-specific:
- pregnancy or lactation
- women of child-bearing age who are sexually active without practising reliable methods of contraception
- any disease or impairment that, in the opinion of the investigator, excludes a subject from participation
- substance abuse (alcohol, medicines, drugs)
- other medical, psychological or social circumstances that would adversely affect a patient's ability to participate adequately in the study or increase the risk to the patient or others in the case of participation.
- insufficient compliance
- subjects in whom MRI cannot be performed (contrast medium allergy, claustrophobia, cardiac pacemaker)
- subjects who are not able to perform CPX
-
Specific:
- pulmonary hypertension of any aetiology other than those specified in the inclusion criteria
- subjects with known intolerance of NO or iloprost or their constituents
- acute decompensated heart failure within 7 days before the invasive procedure
- haemodynamic instability that would increase the risk of pulmonary arterial reactivity testing
- arterial hypotension
- anaemia (Hb < 10 g/dl)
- decompensated symptomatic polycythaemia
- thrombocytopenia (< 50,000/μl)
- secondary impairment of organic (renal, hepatic) function
- other sources of pulmonary blood flow which render the measurement of the blood flow to the lungs and pulmonary vascular resistance impossible
- obstruction of pulmonary blood outflow
- left ventricular diseases
- significant valvular diseases other than tricuspid or pulmonary regurgitation
- pericardial constriction
- history of stroke, myocardial infarction or life-threatening arrhythmia within 6 months before screening
- bronchopulmonary dysplasia or other chronic lung diseases
- history of significant pulmonary embolism
- other relevant diseases (e.g. HIV infection)
- trisomy 21
- Prohibited concomitant medication: Any medication listed below which has not been discontinued at least 30 days prior to screening.
- Unspecified or other significant medication (e.g. medication for diabetes or immunosuppression)
- Unstable medication, recent changes in dosage regimen
- Drugs to treat pulmonary hypertension (endothelin receptor antagonists, PDE-5 antagonists, prostanoids. (Specific pulmonary vasodilators during cardiac catheterisation are allowed.)
- Other medication with vascular action
- Medication that is not compatible with bosentan or that interferes with its metabolism (inhibitors of CYP2C9 or CYP3A4) or that, in the investigator's opinion, may interfere with bosentan treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00266162
Germany | |
Kinderkardiologie Universitätsklinikum Freiburg | |
Freiburg, Baden-Wuerttemberg, Germany, D-79106 | |
Deutsches Herzzentrum Muenchen | |
Munich, Bavaria, Germany, D-80636 | |
Universitätsklinikum Giessen and Marburg | |
Giessen, Hesse, Germany, D-35385 | |
Herz-und Diabeteszentrum NRW | |
Bad Oeynhausen, North Rhine-Westphalia, Germany, D-32545 | |
Universitätsklinikum Schleswig-Holstein Campus Kiel | |
Kiel, North Rhine-Westphalia, Germany, D-24105 | |
Universitätsklinikum des Saarlandes | |
Homburg, Saarland, Germany, D-66421 | |
Universitätsklinikum der Martin-Luther-Universität Halle-Wittenberg | |
Halle, Saxony-Anhalt, Germany, D-06097 | |
Deutsches Herzzentrum Berlin | |
Berlin, Germany, D-13353 |
Principal Investigator: | Ingram Schulze-Neick, MD | German Heart Institute |
ClinicalTrials.gov Identifier: | NCT00266162 History of Changes |
Other Study ID Numbers: |
MP 3.2 01G10210 |
First Posted: | December 16, 2005 Key Record Dates |
Last Update Posted: | May 7, 2008 |
Last Verified: | May 2008 |
Heart Defects, Congenital Eisenmenger Complex Hypertension, Pulmonary |
Pulmonary Heart Disease Pulmonary Circulation Vascular Resistance |
Hypertension Eisenmenger Complex Syndrome Disease Pathologic Processes Vascular Diseases Cardiovascular Diseases Heart Defects, Congenital |
Cardiovascular Abnormalities Heart Diseases Congenital Abnormalities Bosentan Antihypertensive Agents Endothelin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |